James R. Anderson

发表

A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

B. Nathwani, W. Chan, D. Weisenburger, 1997 .

Rural motor vehicle crash risk of death is higher after controlling for injury severity.

James R. Anderson, F. Ullrich, M. Wadman, 2007, The Journal of trauma.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

James R. Anderson, R. Dummer, J. Larkin, 2019, The Lancet. Oncology.

A predictive model for aggressive non-Hodgkin's lymphoma.

Emili Montserrat, Christian Gisselbrecht, Carlo Tondini, 1993, The New England journal of medicine.

18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).

James R. Anderson, D. Rodeberg, S. Spunt, 2016 .

Web-based decision support for clinical trial eligibility determination in an international clinical trials network.

James R. Anderson, F. Ullrich, P. Breitfeld, 2003, Controlled clinical trials.

Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

James R. Anderson, S. Donaldson, A. Pappo, 2004, European journal of cancer.

Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group.

James R. Anderson, G. Reaman, M. O'Leary, 2008, Seminars in oncology.

Imaging features of alveolar soft-part sarcoma: a report from Children's Oncology Group Study ARST0332.

James R. Anderson, S. Spunt, D. Parham, 2014, AJR. American journal of roentgenology.

Comparative accuracy of real-time myocardial contrast perfusion imaging and wall motion analysis during dobutamine stress echocardiography for the diagnosis of coronary artery disease.

James R. Anderson, A. Elhendy, T. Porter, 2004, Journal of the American College of Cardiology.

Diagnostic Accuracy and Prognostic Value of Dobutamine Stress Myocardial Contrast Echocardiography in Patients with Suspected Acute Coronary Syndromes

James R. Anderson, A. Elhendy, T. Porter, 2005, Echocardiography.

Evaluation of diagnostic performance of CT for detection of tumor thrombus in children with Wilms tumor: A report from the Children's Oncology Group

James R. Anderson, K. Karolczuk, J. Dome, 2012, Pediatric blood & cancer.

SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor.

James R. Anderson, M. D. de Caestecker, A. Perantoni, 2012, Journal of pediatric surgery.

CITED1 expression in Wilms' tumor and embryonic kidney.

James R. Anderson, G. Shi, M. D. de Caestecker, 2007, Neoplasia.

Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.

James R. Anderson, S. Donaldson, C. Paidas, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

James R. Anderson, F. Ullrich, D. Romberger, 2002, Anesthesiology.

Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies‐4 and ‐5: A report from the Children's Oncology Group

N. Breslow, James R. Anderson, D. Green, 2012, Pediatric blood & cancer.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

The Management of Synchronous Bilateral Wilms Tumor: A Report from the National Wilms Tumor Study Group

James R. Anderson, P. Argani, D. Green, 2011, Annals of surgery.

Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV.

James R. Anderson, A. Pappo, W. Meyer, 2004, The Journal of pediatrics.

Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.

James R. Anderson, T. Triche, J. Buckley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997.

James R. Anderson, E. Gehan, J. Meza, 2002, Medical and pediatric oncology.

Orbital sarcoma with metastases at diagnosis: A report from the soft tissue sarcoma committee of the Children's Oncology Group

James R. Anderson, D. Rodeberg, T. Yock, 2010, Pediatric blood & cancer.

Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532

James R. Anderson, J. Dome, P. Grundy, 2017, Annals of surgery.

WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.

James R. Anderson, D. Green, J. Dome, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, J. Gastier-Foster, A. Pappo, 2017, Pediatric blood & cancer.

Myogenin , AP 2 b , NOS-1 , and HMGA 2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma

James R. Anderson, J. Gastier-Foster, S. Skapek, 2014 .

Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

James R. Anderson, T. Triche, S. Skapek, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.

James R. Anderson, J. Gastier-Foster, J. Dome, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5.

James R. Anderson, D. Green, J. Dome, 2010, International journal of radiation oncology, biology, physics.

Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations

James R. Anderson, F. Ullrich, H. Gendelman, 2005, Glia.

Comparison of Front-Line Chemotherapy for Intermediate Grade and Follicular Non-Hodgkin’s Lymphoma Using the CAP-BOP Regimens

J. Armitage, P. Bierman, J. Vose, 1996 .

Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Interferon, and Allogeneic Bone Marrow Transplantation in Treating the An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea,

James R. Anderson, S. Woolf, F. Appelbaum, 2013 .

Dropout by Design: Advance Planning for Research Participant Noncompliance

James R. Anderson, T. Schonfeld, 2011, The American journal of bioethics : AJOB.

High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft

J. Armitage, P. Bierman, J. Vose, 1994 .

Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

James R. Anderson, J. Dome, P. Grundy, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor : A Report From the Children ' s Oncology Group Study AREN 0532

James R. Anderson, P. Grundy, E. Perlman, 2022 .

B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor.

James R. Anderson, A. Retik, P. Grundy, 2013, The Journal of urology.

Outbreak of bloodstream infection temporally associated with the use of an intravascular needleless valve.

James R. Anderson, P. Fey, M. Rupp, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

1 Expression in Wilms ’ Tumor and Embryonic Kidney 1

James R. Anderson, M. Caestecker, G. Shi, 2014 .

Obstetric Anesthesia Workforce Survey: Twenty-year Update

James R. Anderson, F. Ullrich, J. Hawkins, 2005 .

Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco.

James R. Anderson, F. Ullrich, K. Patil, 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

James R. Anderson, J. Wolchok, H. Zarour, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: Combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumor

James R. Anderson, F. Ullrich, M. Stevens, 2011, International journal of cancer.

1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)

James R. Anderson, J. Kirkwood, A. Ribas, 2021, Annals of Oncology.

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

James R. Anderson, J. Larkin, A. Ribas, 2018 .

Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5.

James R. Anderson, D. Green, A. Davidoff, 2012, Journal of pediatric surgery.

Grading of Non-Rhabdomyosarcoma Soft Tissue Sarcoma in Children and Adolescents: A Comparison of Parameters Used for the FNCLCC and POG systems

James R. Anderson, S. Spunt, J. Khoury, 2010 .

Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen.

James R. Anderson, C. Bollard, C. Patte, 2016 .

Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop.

James R. Anderson, F. Ullrich, M. Stevens, 2006, The Journal of urology.

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols

P. Sorensen, James R. Anderson, T. Triche, 2001, Sarcoma.

Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B‐NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1

James R. Anderson, G. Leverger, S. Perkins, 2018, British journal of haematology.

Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer

James R. Anderson, A. Ganti, E. Reed, 2006, Medical oncology.

Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a cancer and leukemia group B study

James R. Anderson, Mark R. Green, K. Propert, 2004, Cancer Chemotherapy and Pharmacology.

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

G. Getz, M. Meyerson, James R. Anderson, 2014, Cancer discovery.

Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.

James R. Anderson, J. Gastier-Foster, J. Dome, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

James R. Anderson, D. Rodeberg, W. Meyer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The immunophenotype of T‐lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report

D. Campana, Lynette M. Smith, James R. Anderson, 2012, British journal of haematology.

Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, C. Paidas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low‐Risk Clinical Features: A Report From the Children's Oncology Group

James R. Anderson, J. Gastier-Foster, S. Skapek, 2016, Pediatric blood & cancer.

Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984–1997: A report from the Children's Oncology Group

James R. Anderson, S. Donaldson, D. Rodeberg, 2010, Pediatric blood & cancer.

Prognostic F actors a nd C linical O utcomes i n C hildren a nd Adolescents W ith M etastatic R habdomyosarcoma —A R eport From t he I ntergroup R habdomyosarcoma S tudy I V

James R. Anderson, S. Donaldson, C. Paidas, 2003 .

Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).

James R. Anderson, C. Coffin, Lynn M. Smith, 2002, Medical and pediatric oncology.

Favorable outcome for children with paratesticular alveolar history rhabdomysosarcoma

James R. Anderson, E. Wiener, William H Meyer, 2004, Pediatric blood & cancer.

Soft-Tissue Sarcomas of the Diaphragm: A Report From the Intergroup Rhabdomyosarcoma Study Group From 1972 to 1997

James R. Anderson, S. Donaldson, W. Crist, 2000, Journal of pediatric hematology/oncology.

Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.

James R. Anderson, D. Rodeberg, C. Paidas, 2003, Journal of pediatric surgery.

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2015, International journal of radiation oncology, biology, physics.

Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.

N. Breslow, James R. Anderson, D. Green, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adequate Disinfection of a Split-Septum Needleless Intravascular Connector with a 5-Second Alcohol Scrub

James R. Anderson, T. V. Van Schooneveld, P. Fey, 2012, Infection Control & Hospital Epidemiology.

Prospective, Controlled, Cross-Over Trial of Alcohol-Based Hand Gel in Critical Care Units

Valerie Smith, James R. Anderson, M. Rupp, 2008, Infection Control & Hospital Epidemiology.

Systemic anaplastic large‐cell lymphoma: Results from the non‐Hodgkin's lymphoma classification project

B. Nathwani, D. Weisenburger, R. Gascoyne, 2001, American journal of hematology.

Peripheral T‐cell lymphoma in childhood and adolescence a clinicopathologic study of 22 patients

D. Weisenburger, J. Armitage, J. Vose, 1993, Cancer.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups.

James R. Anderson, M. Stevens, D. Rodeberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, S. Skapek, D. Hawkins, 2015, Archives of pathology & laboratory medicine.

Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.

James R. Anderson, M. Link, W. Meyer, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow‐positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report

Lynette M. Smith, James R. Anderson, W. Sanger, 2014, British journal of haematology.

Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

James R. Anderson, Daniel F. Comiskey, D. Chandler, 2013, Neoplasia.

Aberrant activation, nuclear localization, and phosphorylation of yes‐associated protein‐1 in the embryonic kidney and Wilms tumor

James R. Anderson, M. D. de Caestecker, J. Dome, 2014, Pediatric blood & cancer.

Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia.

James R. Anderson, M. Devidas, 2013, Clinical investigation.

Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.

James R. Anderson, M. Stevens, M. Carli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, S. Donaldson, D. Rodeberg, 2019, Cancer.

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O

James R. Anderson, J. Meza, W. Meyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia

James R. Anderson, N. Sebire, T. Chagtai, 2014, PloS one.

Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumor

A. Ashworth, James R. Anderson, T. Chagtai, 2011, Genes, chromosomes & cancer.

treatment outcome. The Nebraska Lymphoma Study Group lymphoma: associations with histology, clinical characteristics, and Chromosomal abnormalities in untreated patients with non-Hodgkin's

D. Weisenburger, J. Armitage, James R. Anderson, 2011 .

Long-term Outcomes for Infants With Very Low Risk Wilms Tumor Treated With Surgery Alone in National Wilms Tumor Study-5

N. Breslow, James R. Anderson, R. Macklis, 2010, Annals of surgery.

Burkitt's and Burkitt‐like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience *

James R. Anderson, W. Sanger, S. Perkins, 2003, British journal of haematology.

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

James R. Anderson, J. Dome, P. Grundy, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: A report from the Children's Oncology Group

James R. Anderson, J. Lynch, F. Barr, 2011, Pediatric blood & cancer.

Children's Oncology Group's 2013 blueprint for research: Renal tumors

James R. Anderson, A. Naranjo, J. Dome, 2013, Pediatric blood & cancer.

Obstetric anesthesia workforce survey: twenty-year update.

James R. Anderson, F. Ullrich, J. Hawkins, 2005, Anesthesiology.

Problem gambling in the partner of the emergency department patient as a risk factor for intimate partner violence.

James R. Anderson, M. Wadman, R. Muelleman, 2002, The Journal of emergency medicine.

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group

James R. Anderson, M. Delorenzi, T. Triche, 2015, Clinical Cancer Research.

Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

James R. Anderson, J. Gastier-Foster, S. Skapek, 2013, American journal of clinical pathology.

A Novel Algorithm for Simpli fi cation of Complex Gene Classi fi ers in Cancer

James R. Anderson, T. Triche, J. Gastier-Foster, 2013 .

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.

Charles H. Yoon, A. Hauschild, James R. Anderson, 2019, Future oncology.

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, D. Rodeberg, S. Spunt, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paediatric Non-Hodgkin’s Lymphomas: The Childrens’ Cancer Study Group Experience

James R. Anderson, J. Kersey, S. Siegel, 1982 .

Myelodysplastic syndrome after autologous transplant for lymphoma [7]

J. Vose, James R. Anderson, A. Kessinger, 1994 .

Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

James R. Anderson, J. Meza, A. Pappo, 2017, Cancer.

Myogenin, AP2&bgr;, NOS-1, and HMGA2 Are Surrogate Markers of Fusion Status in Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children’s Oncology Group

Stephen X Skapek, Julie M Gastier-Foster, James R. Anderson, 2014, The American journal of surgical pathology.

Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.

James R. Anderson, J. Meza, A. Pappo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group.

James R. Anderson, D. Rodeberg, C. Paidas, 2008, Journal of pediatric surgery.

One‐ and two‐stage designs for phase II window studies

James R. Anderson, M. Devidas, M. Chang, 2007, Statistics in medicine.

Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

James R. Anderson, A. Pappo, W. Meyer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of NAT and GST polymorphisms with non‐Hodgkin's lymphoma: a population‐based case–control study

D. Weisenburger, James R. Anderson, S. Gapstur, 2005, British journal of haematology.

Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection.

James R. Anderson, S. Swindells, Daniel G Cobos, 2002, AIDS.

MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours

Richard A. Moore, Daoud M. Meerzaman, D. Wheeler, 2015, Nature Communications.

Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V

James R. Anderson, S. Donaldson, A. Pappo, 2001, Journal of pediatric hematology/oncology.

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

James R. Anderson, S. Donaldson, D. Rodeberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study

David W. Henry, James R. Anderson, S. Spunt, 2013, Pediatric blood & cancer.

Gain of 1q is associated with inferior event‐free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group

James R. Anderson, J. Dome, P. Grundy, 2013, Cancer.

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

James R. Anderson, R. Gelber, K. Cain, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study‐5 (NWTS‐5)

James R. Anderson, D. Green, P. Grundy, 2018, Pediatric blood & cancer.

Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study.

James R. Anderson, J. Dome, P. Grundy, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

James R. Anderson, D. Green, J. Dome, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma

James R. Anderson, D. Rodeberg, S. Spunt, 2018, Cancer.

Patterns of chemotherapy‐induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, D. Hawkins, A. Rosenberg, 2017, Pediatric blood & cancer.

Patterns of chemotherapy‐induced toxicities in younger children and adolescents with rhabdomyosarcoma

James R. Anderson, A. Pappo, S. Spunt, 2012, Cancer.

Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group

James R. Anderson, C. Paidas, J. Breneman, 2004, Pediatric blood & cancer.

Myelodysplastic syndrome after autologous transplant for lymphoma [letter; comment]

J. Vose, James R. Anderson, A. Kessinger, 1994 .

Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2011, International journal of radiation oncology, biology, physics.

Sarcoma REGIONAL NODAL INVOLVEMENT AND PATTERNS OF SPREAD ALONG IN-TRANSIT PATHWAYS IN CHILDREN WITH RHABDOMYOSARCOMA OF THE EXTREMITY : A REPORT FROM THE CHILDREN ’ S ONCOLOGY GROUP

James R. Anderson, S. Donaldson, D. Rodeberg, 2011 .

What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?

James R. Anderson, S. Donaldson, M. Link, 2001, Cancer.

The frequency and distribution of cardiovascular disease risk factors among Nebraska women enrolled in the WISEWOMAN screening program.

James R. Anderson, F. Ullrich, Wanqing Zhang, 2008, Journal of women's health.

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Thomas O Jemielita, James R. Anderson, Meihua Wang, 2019, Journal of Immunotherapy for Cancer.

Nasopharyngeal carcinoma—a retrospective review of patients less than thirty years of age: A report from childrens cancer study group

James R. Anderson, W. Wara, D. Hammond, 1981, Cancer.

Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence

James R. Anderson, S. Donaldson, C. Paidas, 2001, Cancer.

Pretreatment TNM staging of childhood rhabdomyosarcoma

James R. Anderson, E. Gehan, H. Maurer, 1997, Cancer.

Sera proteomic biomarker profiling in HIV‐1 infected subjects with cognitive impairment

James R. Anderson, P. Ciborowski, Jayme L Horning, 2008, Proteomics. Clinical applications.

Marginal Z one B -Cell L ymphoma: A C linical C omparison of N odal a nd M ucosa-Associate d L ymphoid T issue T ypes

B. Nathwani, D. Weisenburger, J. Armitage, 1999 .

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, D. Rodeberg, D. Hawkins, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early results from Children's Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).

James R. Anderson, D. Rodeberg, D. Hawkins, 2015 .

Rhabdomyosarcoma: many similarities, a few philosophical differences.

James R. Anderson, S. Donaldson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Susceptibility of enterococci to daptomycin is dependent upon testing methodology.

James R. Anderson, T. V. Van Schooneveld, P. Fey, 2013, Diagnostic microbiology and infectious disease.

PAX‐FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report

James R. Anderson, T. Triche, J. Gastier-Foster, 2013, Pediatric blood & cancer.

Childhood and adolescent large‐cell lymphoma (LCL): A review of the children's cancer group experience

James R. Anderson, S. Perkins, J. Finlay, 2003, American journal of hematology.

Plasma proteomic analysis of simian immunodeficiency virus infection of rhesus macaques.

James R. Anderson, H. Gendelman, H. Fox, 2010, Journal of proteome research.

Hepatic Metastasis at Diagnosis in Patients With Wilms Tumor is not an Independent Adverse Prognostic Factor for Stage IV Wilms Tumor: A Report From the Children's Oncology Group/National Wilms Tumor Study Group

James R. Anderson, D. Green, J. Dome, 2009, Annals of surgery.

Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia

S. Raimondi, James R. Anderson, W. Sanger, 2007, Genes, chromosomes & cancer.

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

James R. Anderson, J. Meza, A. Pappo, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.

Karen Morano, Fran Laurie, Charles A Enke, 2012, International journal of radiation oncology, biology, physics.

Inappropriate use of urinary catheters: a prospective observational study.

James R. Anderson, M. Rupp, E. Hermsen, 2012, American journal of infection control.

Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents

James R. Anderson, S. Spunt, D. Parham, 2010, Cancer.

Local control for high-grade Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) assigned to radiation therapy on xxx: A report from the xxx.

James R. Anderson, S. Donaldson, D. Rodeberg, 2021, International journal of radiation oncology, biology, physics.

Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance.

James R. Anderson, P. Fey, M. Rupp, 2004, American journal of infection control.

Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

James R. Anderson, D. Rodeberg, S. Spunt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.

James R. Anderson, A. Arance, P. Ruff, 2021 .

Anthropomorphic measurements and event‐free survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group

James R. Anderson, D. Green, J. Dome, 2009, Pediatric blood & cancer.

Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve Outcome

Lynette M. Smith, James R. Anderson, S. Donaldson, 2004, Clinical Cancer Research.

Prognostic Value of Dobutamine Stress Myocardial Contrast Perfusion Echocardiography

James R. Anderson, A. Elhendy, T. Porter, 2005, Circulation.

A novel algorithm for simplification of complex gene classifiers in cancer.

Stephen X Skapek, Samuel L Volchenboum, Timothy J Triche, 2013, Cancer research.

Prognostic factors and outcome in children with metastatic rhabdomyosarcoma - a report from the intergroup rhabdomyosarcoma study IV

James R. Anderson, S. Donaldson, M. Link, 2001 .

Rhabdomyosarcoma in infants younger than 1 year

James R. Anderson, S. Donaldson, D. Rodeberg, 2011, Cancer.

Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

James R. Anderson, D. Hawkins, M. Carli, 2015, Pediatric blood & cancer.

Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS‐IV in intermediate risk rhabdomyosarcoma: A report from the Children's Oncology Group

James R. Anderson, J. Neglia, D. Hawkins, 2008, Pediatric blood & cancer.

Routine brain imaging is unwarranted in asymptomatic patients with rhabdomyosarcoma arising outside of the head and neck region that is metastatic at diagnosis

James R. Anderson, A. Pappo, S. Spunt, 2001, Cancer.

The Effect of Radiation Therapy Techniques (IMRT vs. 3DCRT) on Outcome in Patients with Intermediate Risk Rhabdomyosarcoma Enrolled in COG D9803: A Report from COG

James R. Anderson, J. Meza, S. Donaldson, 2010 .

Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group.

James R. Anderson, J. Stoner, W. Meyer, 2010, Journal of pediatric surgery.

Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee.

James R. Anderson, S. Donaldson, D. Rodeberg, 2014 .

Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS).

James R. Anderson, J. Michalski, D. Hawkins, 2010 .

Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.

James R. Anderson, D. Rodeberg, D. Hawkins, 2014, European journal of cancer.

Effect of Hospital-Wide Chlorhexidine Patient Bathing on Healthcare-Associated Infections

James R. Anderson, M. Rupp, T. Vanschooneveld, 2012, Infection Control & Hospital Epidemiology.

A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: Results from the Children’s Oncology Group AREN0321 study.

James R. Anderson, J. Dome, P. Grundy, 2014 .

Influence of noncompliance with radiation therapy protocol guidelines and operative bed recurrences for children with rhabdomyosarcoma and microscopic residual disease: a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Rodeberg, 2011, International journal of radiation oncology, biology, physics.

Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Children’s Oncology Group AREN0532.

James R. Anderson, J. Dome, P. Grundy, 2015 .

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

Impact of persistent minimal residual disease post‐consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report

Lynette M. Smith, James R. Anderson, W. Sanger, 2015, British Journal of Haematology.

Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions.

James R. Anderson, J. Neff, J. Bridge, 1993, Cancer genetics and cytogenetics.

Omission of lung radiation in patients with stage IV favorable histology Wilms Tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Children's Oncology Group study AREN0533.

James R. Anderson, J. Dome, P. Grundy, 2015 .

Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Children's Oncology Group study AREN0533.

James R. Anderson, J. Dome, P. Grundy, 2014 .

Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332.

James R. Anderson, R. Randall, F. Laurie, 2014 .

The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.

James R. Anderson, S. Donaldson, J. Michalski, 2013, International journal of radiation oncology, biology, physics.

Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.

James R. Anderson, S. Donaldson, D. Hawkins, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

James R. Anderson, J. Meza, S. Donaldson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991.

James R. Anderson, E. Gehan, J. Breneman, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: Report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991.

James R. Anderson, R. Heyn, M. Wharam, 2000, Medical and pediatric oncology.

Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.

B. Nathwani, D. Weisenburger, J. Armitage, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

B. Nathwani, D. Weisenburger, J. Armitage, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project.

D. Weisenburger, J. Armitage, James R. Anderson, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.

J. Armitage, P. Bierman, J. Vose, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of cellular proliferation and histologic grade in follicular lymphoma.

W. Chan, D. Weisenburger, J. Armitage, 1995, Blood.

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial.

James R. Anderson, M. Tempero, D. Colcher, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of survival by tumor response.

J R Anderson, James R. Anderson, R. Gelber, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study.

James R. Anderson, J. Finlay, A. Evans, 1996, Medical and pediatric oncology.

Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group.

James R. Anderson, R. Sposto, S. Siegel, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).

James R. Anderson, J. Kersey, S. Siegel, 1983, The New England journal of medicine.

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

J. Armitage, James R. Anderson, M. Somerfield, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. The Nebraska Lymphoma Study Group.

D. Weisenburger, J. Armitage, James R. Anderson, 1990, Blood.

p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.

W. Chan, T. Greiner, D. Weisenburger, 1996, Blood.

High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

J. Armitage, P. Bierman, J. Vose, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma.

W. Chan, T. Greiner, D. Weisenburger, 1996, Blood.

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report

James R. Anderson, W. Sanger, S. Perkins, 2013, Leukemia.

Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.

D. Weisenburger, J. Armitage, P. Bierman, 1991, The American journal of medicine.

Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection.

James R. Anderson, H. Gendelman, S. Swindells, 2001, The Journal of infectious diseases.

Mutation analysis for cystic fibrosis to determine carrier status in 167 sperm donors from the Nebraska genetic semen bank

James R. Anderson, W. Sanger, M. Traystman, 1994, Human mutation.

Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).

James R. Anderson, D. Rodeberg, D. Hawkins, 2014 .

Ifosfamide and Etoposide Are Superior to Vincristine and Melphalan for Pediatric Metastatic Rhabdomyosarcoma When Administered With Irradiation and Combination Chemotherapy: A Report From the Intergroup Rhabdomyosarcoma Study Group

P. Sorensen, James R. Anderson, T. Triche, 2001, Journal of pediatric hematology/oncology.

Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.

James R. Anderson, S. Donaldson, C. Paidas, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.

James R. Anderson, M. Link, J. Breneman, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of central laboratories and remote electronic data capture to risk-adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma.

James R. Anderson, M. Devidas, W. London, 2010, Seminars in oncology.

Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group.

J. Armitage, P. Bierman, J. Vose, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.

James R. Anderson, D. Hawkins, W. Meyer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma.

James R. Anderson, C. Paidas, A. Pappo, 2000, Journal of pediatric surgery.

Intergroup R habdomyosarcoma S tudy-IV: R esults f or Patients W ith N onmetastatic D isease

James R. Anderson, J. Meza, S. Donaldson, 2001 .

High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

James R. Anderson, J. Schlom, M. Tempero, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Breast and Cervical Cancer Screening Among Low-income Women in Nebraska: Findings from the Every Woman Matters Program, 1993–2004

James R. Anderson, F. Ullrich, Wanqing Zhang, 2008, Journal of health care for the poor and underserved.